Funding for this research was provided by:
Alexander S. Onassis Public Benefit Foundation (2017)
Horizon 2020 Framework Programme (668353)
Article History
Received: 31 October 2019
Accepted: 24 December 2019
First Online: 15 January 2020
Ethics approval and consent to participate
: Not applicable
: Not applicable
: The authors declare no conflict of interest. GPP is Full Member and National Representative at the European Medicines Agency, Committee for Human Medicinal Products (CHMP)–Pharmacogenomics working Party in Amsterdam, the Netherlands.